Éric Dansin

12.2k total citations · 1 hit paper
113 papers, 2.4k citations indexed

About

Éric Dansin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Éric Dansin has authored 113 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 62 papers in Oncology and 24 papers in Neurology. Recurrent topics in Éric Dansin's work include Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (25 papers) and Myasthenia Gravis and Thymoma (20 papers). Éric Dansin is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (25 papers) and Myasthenia Gravis and Thymoma (20 papers). Éric Dansin collaborates with scholars based in France, United States and Italy. Éric Dansin's co-authors include Benjamin Besse, Julien Mazières, Fabrice Barlési, P. Fournel, Denis Moro‐Sibilot, Marie Wislez, Alexis B. Cortot, Solange Peters, Julie Milia and Michèle Beau‐Faller and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Éric Dansin

105 papers receiving 2.3k citations

Hit Papers

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic ... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
    2013 489 citations Julien Mazières, Solange Peters et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Dansin France 19 1.8k 1.4k 376 330 293 113 2.4k
Zhouguang Hui China 22 1.1k 0.6× 575 0.4× 256 0.7× 217 0.7× 378 1.3× 145 1.7k
Dominique Grunenwald France 28 2.1k 1.2× 1.3k 0.9× 299 0.8× 281 0.9× 252 0.9× 86 3.3k
Yasuhisa Ohde Japan 27 1.6k 0.9× 875 0.6× 356 0.9× 342 1.0× 412 1.4× 160 2.5k
B. Maat Netherlands 12 1.2k 0.7× 635 0.5× 177 0.5× 325 1.0× 328 1.1× 21 2.1k
Andrew Weickhardt Australia 23 2.3k 1.3× 2.3k 1.6× 967 2.6× 527 1.6× 265 0.9× 111 3.4k
Antoine Adenis France 24 1.1k 0.6× 698 0.5× 289 0.8× 164 0.5× 83 0.3× 84 2.0k
Zefen Xiao China 25 1.2k 0.7× 603 0.4× 321 0.9× 185 0.6× 228 0.8× 144 2.0k
Michael Offin United States 23 1.5k 0.8× 1.1k 0.8× 550 1.5× 492 1.5× 138 0.5× 97 2.1k
B.Y. Yeap United States 20 1.0k 0.6× 805 0.6× 563 1.5× 238 0.7× 149 0.5× 65 2.0k
Giuseppe Roberto D’Agostino Italy 30 1.1k 0.6× 669 0.5× 231 0.6× 286 0.9× 396 1.4× 125 2.4k

Countries citing papers authored by Éric Dansin

Since Specialization
Citations

This map shows the geographic impact of Éric Dansin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Dansin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Dansin more than expected).

Fields of papers citing papers by Éric Dansin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Dansin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Dansin. The network helps show where Éric Dansin may publish in the future.

Co-authorship network of co-authors of Éric Dansin

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Dansin. A scholar is included among the top collaborators of Éric Dansin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Dansin. Éric Dansin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dansin, Éric, Jennifer Arrondeau, Daniel Jiménez, et al.. (2025). 425P: Real-world data of everolimus in patients with thymic epithelial tumors (TETs). Journal of Thoracic Oncology. 20(3). S246–S247.
2.
Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations
3.
Masip, J. Remon, Paolo Bironzo, N. Girard, et al.. (2024). LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma. Annals of Oncology. 35. S1270–S1270. 3 indexed citations
4.
Baudin, Éric, Christine Do Cao, Éric Dansin, et al.. (2023). Surgery of primary lung carcinoid tumors at metastatic stage: A national study from the French Group of Endocrine Tumors ( GTE ) and ENDOCAN‐RENATEN network. Journal of Neuroendocrinology. 35(10). e13331–e13331. 1 indexed citations
5.
Pérol, Olivia, Pierre Lebailly, Bénédicte Clin, et al.. (2023). A Multicenter Study to Assess a Systematic Screening of Occupational Exposures in Lung Cancer Patients. International Journal of Environmental Research and Public Health. 20(6). 5068–5068. 6 indexed citations
6.
7.
Baize, Nathalie, I. Monnet, Laurent Greillier, et al.. (2019). OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial. Journal of Thoracic Oncology. 14(10). S246–S246. 5 indexed citations
8.
Dansin, Éric, Laurent Mhanna, Laurent Greillier, et al.. (2018). Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. Journal of Thoracic Oncology. 13(11). 1762–1770. 50 indexed citations
9.
Cao, Christine Do, Aurélie Dumont, Y Robin, et al.. (2018). Tumeurs neuroendocrines primitives du sein : mythe ou réalité ? Une revue de la littérature. Bulletin du Cancer. 105(4). 431–439. 9 indexed citations
10.
Dansin, Éric, M. Kerjouan, Julien Mazières, et al.. (2017). P2.04-006 Updated Incidence of Thymic Epithelial Tumors (TET) in France and Clinical Presentation at Diagnosis. Journal of Thoracic Oncology. 12(1). S1000–S1000. 2 indexed citations
11.
12.
Mazières, Julien, Fabrice Barlési, Thomas Filleron, et al.. (2015). Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Annals of Oncology. 27(2). 281–286. 219 indexed citations
13.
Leroy, Tanguy, et al.. (2013). Syndrome des anticorps anti-Hu : difficultés diagnostiques et thérapeutiques. Revue des Maladies Respiratoires. 30(7). 563–566. 1 indexed citations
14.
Dansin, Éric, Sophie Cousin, Géraldine Lauridant, & B. Mennecier. (2013). Bévacizumab en oncologie thoracique : résultats et aspects pratiques. Revue de Pneumologie Clinique. 69(3). 159–169. 1 indexed citations
15.
Dansin, Éric, Saverio Cinieri, Pilar Garrido, et al.. (2012). MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer. 76(3). 373–379. 25 indexed citations
16.
Borget, Isabelle, Jacques Cadranel, Jean‐Pierre Pignon, et al.. (2011). Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. European Respiratory Journal. 39(1). 172–179. 27 indexed citations
17.
Ferté, Charles, Benjamin Besse, Éric Dansin, et al.. (2010). Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Annals of Oncology. 21(6). 1385–1387. 8 indexed citations
18.
Penel, Nicolas, S. Taïeb, L. Ceugnart, et al.. (2008). Report of Eight Recent Cases of Locally Advanced Primary Pulmonary Artery Sarcomas: Failure of Doxorubicin-Based Chemotherapy. Journal of Thoracic Oncology. 3(8). 907–911. 32 indexed citations
19.
Zatloukal, Petr, Radj Gervais, Johan Vansteenkiste, et al.. (2008). Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(8). 894–901. 22 indexed citations
20.
Giaccone, Giuseppe, Egbert F. Smit, Maja J.A. de Jonge, et al.. (2004). Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer. European Journal of Cancer. 40(5). 667–672. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhouguang Hui Breakdown of academic impact, for papers by Dominique Grunenwald Breakdown of academic impact, for papers by Yasuhisa Ohde Breakdown of academic impact, for papers by B. Maat Breakdown of academic impact, for papers by Andrew Weickhardt Breakdown of academic impact, for papers by Antoine Adenis Breakdown of academic impact, for papers by Zefen Xiao Breakdown of academic impact, for papers by Michael Offin Breakdown of academic impact, for papers by B.Y. Yeap Breakdown of academic impact, for papers by Giuseppe Roberto D’Agostino
Rankless by CCL
2026